PolyNovo Biomaterials Pty Ltd
PolyNovo Biomaterials Pty Ltd, a wholly owned subsidiary of Calzada Ltd (ASX:CZD), is focused on leveraging its novel patented family of biodegradable polymers NovoSorb™ for use in medical devices. The NovoSorb™ platform has impressive versatility allowing new approaches to the treatment of many diseases and injuries.
PolyNovo developed NovoSorb™ a family of biodegradable medical polymers designed to overcome the limitations of existing biomaterials such as PLA/PGA and collagen.
NovoSorb™ polymers are based on polyurethanes, a versatile polymer family used in many medical and industrial applications. The versatility of the NovoSorb™ chemistry can, in many cases, be leveraged by biomedical engineers to design devices tailored to the end user requirements.
Medical Devices Development
PolyNovo has formed two joint ventures with Associate Professor John Greenwood: NovoSkin and NovoWound.
NovoSkin is developing a two stage treatment for full thickness burns comprising a Biodegradable Temporising Matrix (‘BTM’) and Composite Cultured Skin (‘CCS’), with the ultimate goal of abolishing the need for skin grafts and improving the quality of the resulting tissue and the speed of the return to function. The first BTM clinical trial is underway at the Royal Adelaide Hospital.
NovoWound has developed an improved foam dressing for use in Negative Pressure Wound Therapy (‘NPWT’).